title: Transdermal drug delivery treatment for overactive bladder.
abstract: Overactive bladder is commonly treated with oral anticholinergic drugs such as oxybutynin chloride. Although oral anticholinergic agents have been effective in controlling urinary urgency and incontinence, adverse events, particularly dry mouth, often cause patients to discontinue oral therapy and to endure incontinence. Oxybutynin can be delivered transcutaneously, maintaining the efficacy of oral oxybutynin while significantly minimizing side effects (e.g., dry mouth) that may complicate therapy. By avoiding hepatic and gastrointestinal metabolism of oxybutynin, less N-desethyloxybutynin (N-DEO) is produced and this compound is deemed to be responsible for anticholinergic side effects such as dry mouth. This novel oxybutynin formulation offers patients with OAB and urge urinary incontinence a well-tolerated option for managing the symptoms of overactive bladder.
authors.affiliation: Vanderbilt University Medical Center, Cleveland Clinic Florida, Weston, FL 33331, USA.
authors.forename: Roger R
authors.initials: RR
authors.lastname: Dmochowski
authors.forename: Jonathan S
authors.initials: JS
authors.lastname: Starkman
authors.forename: G Willy
authors.initials: GW
authors.lastname: Davila
mesh_terms: D000279:Administration, Cutaneous; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D006801:Humans; D008333:Mandelic Acids / Q000008:administration & dosage* / Q000493:pharmacokinetics; D018727:Muscarinic Antagonists / Q000008:administration & dosage* / Q000493:pharmacokinetics; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
chemical_list: D008333:Mandelic Acids; D018727:Muscarinic Antagonists; C005419:oxybutynin